Aurinia Pharmaceuticals to Present at Upcoming January Investor Conferences

Aurinia Pharmaceuticals Inc. AUPH (the "Company") today announced that members of the management team will participate in two upcoming virtual investor conferences.

• H.C. Wainwright Virtual BioConnect 2022 Conference. On-demand presentation available Monday, January 10, 2022, beginning at 7:00 a.m. EST thru Thursday, January 13, 2022 (access here)
• J.P Morgan 40^th Annual Healthcare Conference. Presentation to be hosted on Thursday, January 13, 2022 at 9:45 am EST (access here)

Interested parties can also register and access these presentations under "News/Events" through the "Investors" section of the Aurinia corporate website at www.auriniapharma.com.

ABOUT AURINIA

Aurinia is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. In January 2021, the Company introduced the first FDA-approved oral therapy indicated for the treatment of adult patients with active lupus nephritis (LN). Aurinia's head office is in Victoria, British Columbia; its U.S. commercial hub is in Rockville, Maryland; and the Company focuses development efforts globally.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220104005906/en/